The EC approved Libtayo – a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells – based on data from the global open-label, multi-centre phase 3 EMPOWER ...

to produce optimized human antibodies and bispecific antibodies. Its marketed products include EYLEA, Dupixent, Libtayo, Kevzara, and others. On March 14, Evan Seigerman, an analyst from BMO ...

These ready-made antibodies are suitable for developing selective and sensitive assays for bioanalysis and drug monitoring of cemiplimab. Cemiplimab acts as a checkpoint inhibitor by binding to PD-1 ...

SAFEbody is a masking technology that aims to ensure that antibodies are only activated ... its Regeneron-partnered PD-1 checkpoint inhibitor Libtayo (cemiplimab), which still has modest sales ...

CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo ...